Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

December 25, 2027

Study Completion Date

December 25, 2028

Conditions

Advanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK Fusion

Interventions

DRUG

ICP-723

ICP-723 tablet administered orally，once a day，for every 28 days as one cycle

Trial Locations (1)

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY